Last reviewed · How we verify
SB681323
At a glance
| Generic name | SB681323 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS (PHASE2)
- P38 Mitogen-activated Protein (Map) Kinase Inhibitor (SB-681323)Study In Patients With Neuropathic Pain (PHASE2)
- To Assess the Excretion Balance and Pharmacokinetics of a Single Oral Dose of [14C]SB-681323 in Healthy Adult Males (PHASE1)
- A Single Dose Of Compound SB-681323 Compared To Prednisolone On A Protein That Is an Indicator For Rheumatoid Arthritis (PHASE2)
- SB-681323 In Subjects With Rheumatoid Arthritis (PHASE2)
- A Study To Look At The Safety Of SB-681323 In Healthy Adult Subjects After Intravenous Administration Of A Single Dose (PHASE1)
- SB-681323-Methotrexate Interaction Study (PHASE1)
- Safety And Anti-Inflammatory Effect Of SB681323 In Patients With Chronic Obstructive Pulmonary Disease (COPD) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SB681323 CI brief — competitive landscape report
- SB681323 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI